206 care center directors sign a letter citing clinical consequences if decision moves forward.
- About the CF Foundation
- Our Research Approach
- Clinical Trials
- Public Policy
- Our Advocacy Work
- Care Centers
- CFTR Modulators
- Diversity, Equity, and Inclusion
- Get Involved
- Infection Prevention and Control
- Lung Transplantation
- Patient Registry
- Researcher Resources
The physical footprint of the Cystic Fibrosis Foundation Therapeutics Lab grew by about a third this year, enabling startup companies and industry scientists to work and learn alongside lab staff.
The investment will go toward finishing a Phase 2a clinical trial for an anti-infective to treat chronic infections in people with CF.
Barisic will transition from current role as Chief Financial and Administrative Officer in January 2023
Vertex’s copay assistance changes add an undue burden for people living with an already expensive, challenging lifelong disease.
Bill will jump-start rebuilding of the antibiotics pipeline that is vital to stave off a looming pandemic.
Results show that people on Trikafta® enrolled in the six-week study were able to safely stop taking one of the two common CF medications without negatively affecting their health.
The Cystic Fibrosis Foundation is providing up to $5 million to develop a method to deliver a healthy copy of the CFTR gene into the lung cells of people with CF that is unlikely to trigger an immune system response.
Addressing variability in newborn screening can prevent missed diagnoses and delays in early care intervention.
Orkambi® is now approved for use in children with cystic fibrosis ages 1-2 years who have two F508del mutations. This is the only modulator available to very young children with these mutations.